Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actavis Deal Brings Generics “DNA” To Primary Care Opportunity, CEOs Say

This article was originally published in The Pink Sheet Daily

Executive Summary

Amid challenges in the generics sector, the proposed merger of Forest and Actavis creates uncertainty about how the companies will market their primary care drugs.

You may also be interested in...



Teva’s More Convenient Copaxone Puts Payors In A Bind

Teva Pharmaceutical’s recent launch of a more convenient formulation of its soon-to-be-generic multiple sclerosis blockbuster Copaxone puts payors in a quandary. They must choose whether to position it favorably on formularies, similar to the flexible standing that the original daily injection often enjoys, or restrict access to it in a way that has teeth.

Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel